Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2014 (2014), Article ID 574985, 7 pages
Research Article

Clinical Significance of Survivin Expression in Patients with Urothelial Carcinoma

1Division of General Surgery, Department of Surgery, Shuang Ho Hospital, Taipei Medical University, New Taipei City 23561, Taiwan
2Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, 250 Wu-Hsing Street, Taipei 110, Taiwan
3Department of Biomedical Research, Chiayi Christian Hospital, Chiayi 600, Taiwan
4Department of Pathology, Chiayi Christian Hospital, Chiayi 600, Taiwan
5Division of General Surgery, Department of Urology, Shuang Ho Hospital, Taipei Medical University, New Taipei City 23561, Taiwan
6Department of Urology, Chiayi Christian Hospital, 539 Chung Hsiao Road, Chiayi 600, Taiwan
7Tainan University of Technology, Tainan City 71002, Taiwan

Received 20 October 2013; Accepted 12 December 2013; Published 5 February 2014

Academic Editor: Marco E. M. Peluso

Copyright © 2014 Hsin-An Chen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Background. Survivin is a member of the inhibitors of apoptosis protein family that plays an important role in carcinogenesis. Here, we examined the association between survivin expression and clinical outcome in urothelial carcinoma of the bladder (UCB). Methods. A total of 56 histopathologically confirmed UCB patients were recruited from the Department of Urology of Chiayi Christian Hospital from August 2007 to May 2009. Immunohistochemistry (IHC) was used to detect the survivin expression in tumor tissues. The –31 C/G polymorphism in survivin promoter region was determined by polymerase chain reaction-restricted fragment length polymorphism. Results. The frequency of high survivin expression was significantly higher in muscle-invasive tumors (66.6%) than in non-muscle-invasive tumors (34.2%) ( ) and in poorly differentiated (85.7%) tumors than in moderately differentiated tumors (30.8%) ( ). The higher frequency of risk genotypes (C/C and C/G) was found in the median (72.7%) and high (68.0%) survivin expression groups. The multivariate analysis showed that a high survivin expression level was a potential predictive biomarker of poor overall survival ( ). Conclusion. Our results suggest that the high survivin expression was associated with tumor stage and grade and may present a predictive marker of overall survival in UCB.